ADVANCED CELL TECH INC
			Symbol			ACTC

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Advanced Cell Technology Announces Proxy Results

2009-09-16 11:33 ET - News Release

WORCESTER, Mass. -- (Business Wire)

Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) announced today that shareholders have approved each proposal in the Company’s proxy statement dated August 5, 2009. As a result, the 2005 Stock Incentive Plan has been amended to increase the total number of shares available for issuance and the certificate of incorporation has been amended to increase the authorized shares eligible for issuance by the Company.

“We are pleased that shareholders have elected to approve each of the proposals in the proxy, supporting the Company’s efforts to further develop its stem cell technology platform,” said William M. Caldwell IV, the Company’s Chairman and Chief Executive Officer. “We remain focused on submitting an IND for the RPE program to the FDA for approval to commence a Phase I Clinical Trial prior to the end of the year.”

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.